重大事件
即時報告
8-K
2026-07-10
Autonomix Medical 獲納斯達克確認重新符合最低買入價規則 解除除牌風險
AI 繁中摘要
📄 申報類型：8-K
公司：Autonomix Medical, Inc.（股票代號：AMIX）
事件日期：2026年7月9日
Autonomix Medical 已收到納斯達克上市資格部門通知，確認公司重新符合納斯達克資本市場的連續買入價規則（Bid Price Rule）。
📌 背景：公司於2026年1月14日曾因普通股收盤買入價連續30個交易日低於每股1美元，收到納斯達克違規通知。
📌 合規恢復：經連續10個交易日（2026年6月24日至7月8日）收盤買入價維持在1美元或以上，納斯達克於7月9日發函確認合規，相關事項正式結案。
✅ 對投資者的影響：解除因股價過低導致的潛在除牌風險，短期內有助穩定市場信心。然而，公司仍屬新興成長型企業，投資者應持續關注其基本面和業務進展。
（本摘要僅供參考，不構成投資建議。）
展開英文正文
amix20260709_8k.htm false 0001617867 0001617867 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2026 Autonomix Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41940 47-1607810 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 21 Waterway Avenue, Suite 300 The Woodlands, TX 77380 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (713) 588-6150 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.001 per share AMIX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01. Other Events As previously reported, on January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter did not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. On July 9, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at or above $1.00 per share for the 10 consecutive business days from June 24, 2026 through July 8, 2026. Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: July 10, 2026